ASELIZUMAB: A DETAILED EXPLORATION INTO HUDREG-55

Aselizumab, designated HuDreg-55, signifies a innovative therapeutic agent engineered to bind to C1q. How it works utilizes modulating the traditional complement pathway, potentially delivering clinical advantage in a range of immunological disorders. Prior research demonstrate its potential to d